Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06344416 · ClinicalTrials.gov registry record · NA
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
A NA study of Any Solid Oral Medication, sponsored by Dosentrx.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT06344416 is a NA study of Any Solid Oral Medication that is actively recruiting participants, run by Dosentrx. The registered enrollment target is 200 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06344416, a NA study of Any Solid Oral Medication, is actively recruiting participants, sponsored by Dosentrx.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
Conditions Studied
Interventions
- DEVICE Use of ReX to dispense and monitor solid oral medication therapy.
Study Locations (4)
Minnesota
- Allina - Minneapolis
Texas
- Texas Oncology - Austin
Virginia
- Virginia Cancer Center - Richmond
Wisconsin
- Lumicera - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-03-30 |
| Est. Completion | 2026-01-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06344416
The ClinicalTrials.gov registry entry for NCT06344416 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dosentrx, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Any Solid Oral Medication appearing as the primary indexed condition, and to 1 intervention - of which Use of ReX to dispense and monitor solid oral medication therapy. is the first listed.
NCT06344416 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06344416 about?
NCT06344416 is a clinical study titled "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform". Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on r...
What is the current status of trial NCT06344416?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-03-30. Estimated completion is 2026-01-30.
What conditions does trial NCT06344416 study?
This clinical trial studies the following conditions: Any Solid Oral Medication.
What interventions are being tested in trial NCT06344416?
The interventions under investigation include: Use of ReX to dispense and monitor solid oral medication therapy. (DEVICE).
Who is sponsoring clinical trial NCT06344416?
This trial is sponsored by Dosentrx, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06344416 being conducted?
This trial has 4 study locations across Minnesota, Texas, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.